TrialCancer2025

Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis.

Ying L Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.